Randomized, Open Label Study of Dasatinib (100mg qd) vs. High-Dose Imatinib (600mg) in Patients With Chronic Phase CML Who Have Had Suboptimal Response After 3-18 Months of Therapy With Imatinib (400mg).
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- 05 Mar 2009 New trial record